IFNG and neoplasm: On days 7, 12, 17, and 22 following A549 cells inoculation, human anti-IFNγ neutralizing mAb or rhIFNγ was injected into mice intraperitoneally, and after 12 h, BSA-, PA-, or OA-treated Vγ9Vδ2-T cells were administered intravenously to tumor-bearing mice, respectively (Fig. 8a).